Cytokinetics (CYTK) Insider Exercise and Sale on 09/23/2025

Rhea-AI Filing Summary

Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK), reported transactions on 09/23/2025. He exercised 2,000 stock options at an exercise price of $10.60 (non-qualified options exercisable since 03/28/2017, expiring 02/28/2027) and acquired 2,000 shares. He simultaneously sold 2,000 shares at $49.28, leaving him with 140,610 shares beneficially owned. The filing was signed by an attorney-in-fact and the box indicating a 10b5-1 plan was checked.

Positive

• 10b5-1 plan box checked, indicating the sale was pursuant to a pre-established trading plan
• Options exercised at $10.60, showing use of vested, long-dated grants rather than new compensation
• Significant retained ownership after the transaction: 140,610 shares remain beneficially owned

Negative

• Insider sale of 2,000 shares was reported, which may be viewed negatively by some investors despite plan protection

Insights

Corporate Governance Expert

TL;DR Insider exercised options and sold shares under a 10b5-1 plan; routine but worth monitoring for pattern changes.

The filing shows a standard exercise of long-dated non-qualified options followed by an immediate sale of the same number of shares. Use of a 10b5-1 plan indicates the sale was executed under a pre-established program, which reduces concerns about opportunistic trading. The remaining beneficial ownership of 140,610 shares suggests continued material insider alignment with shareholders, and the transaction size is modest relative to typical insider stakes.

Securities Analyst

TL;DR Exercise price far below sale price; insider realized value but retained significant holdings.

The holder exercised 2,000 options at $10.60 and sold the resulting shares at $49.28, realizing a substantial per-share spread. This is a common liquidity event for option holders and does not by itself indicate a change in company outlook. The disclosed option expiration date (02/28/2027) confirms these were existing grants. Transaction details appear transparent and consistent with plan-driven dispositions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP Research & Development

3. Date of Earliest Transaction (Month/Day/Year)
09/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/23/2025		M		2,000	A	$10.6	142,610	D
Common Stock	09/23/2025		S		2,000	D	$49.28	140,610	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (Right to Buy)	$10.6	09/23/2025		M			2,000	03/28/2017	02/28/2027	Common Stock	2,000	$0	5,105	D

Explanation of Responses:

	/s/ John O. Faurescu, attorney-in-fact for Dr. Malik	09/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for CYTK?

The Form 4 was filed for Malik Fady Ibraham, EVP Research & Development at Cytokinetics (CYTK).

What transactions were reported on 09/23/2025 for CYTK?

He exercised 2,000 options at $10.60 and sold 2,000 shares at $49.28 on 09/23/2025.

How many CYTK shares does the reporting person own after the transactions?

The filing shows 140,610 shares beneficially owned following the reported transactions.

Were the option grants time-limited or long-dated?

The exercised non-qualified stock options were exercisable since 03/28/2017 and expire on 02/28/2027.

Was the sale executed under a 10b5-1 trading plan?

Yes, the filer checked the box indicating the transaction was made pursuant to a 10b5-1 plan.